Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 30.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,375 shares of the medical research company’s stock after purchasing an additional 788 shares during the period. GAMMA Investing LLC’s holdings in Edwards Lifesciences were worth $312,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth $28,000. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter worth $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth $34,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the 1st quarter worth $34,000. Finally, Pingora Partners LLC purchased a new position in Edwards Lifesciences during the 4th quarter worth $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Evercore ISI cut their price target on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a report on Thursday, July 25th. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Barclays reduced their target price on shares of Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. Bank of America cut shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $82.10.

Edwards Lifesciences Stock Down 0.2 %

Shares of EW traded down $0.12 during trading hours on Monday, reaching $60.71. The company’s stock had a trading volume of 6,149,915 shares, compared to its average volume of 3,949,267. The company has a 50 day moving average of $85.32 and a two-hundred day moving average of $86.58. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market cap of $36.57 billion, a price-to-earnings ratio of 25.76, a P/E/G ratio of 2.57 and a beta of 1.11. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the company posted $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total value of $73,359.20. Following the sale, the vice president now owns 23,890 shares in the company, valued at approximately $2,044,984. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 8,617 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 857 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total value of $73,359.20. Following the completion of the sale, the vice president now directly owns 23,890 shares of the company’s stock, valued at approximately $2,044,984. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,099 shares of company stock worth $2,680,879. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.